The Latest Breaking News on Pharma

Mehmet Oz’s advocacy for the drug hydroxychloroquine in the early days of the COVID-19 pandemic is cited in a new congressional report that accuses former President Donald Trump’s administration of pressuring the Food and Drug Administration to endorse unproven treatments and vaccines.

Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults

Biotech clinical-stage company Algernon Pharmaceuticals Inc.

The DEA recently abandoned a proposal for placing five tryptamines as Schedule I under the Controlled Substances Act.

The biotech industry thrived during the pandemic. However, that seems to be fading as the pandemic situation has relaxed. And given the inherent volatility of penny stocks, iBio (IBIO), VistaGen Therapeutics (VTGN), and Timber Pharmaceuticals (TMBR) might be best avoided amid the broader market turmoil. Read more….

Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring

Key Takeaways: Viva Biotech’s eked out a scant 5% revenue growth in the first half of the year and fell into the red, even as other peers in China’s CXO sector performed much better Changing values of the company’s investments are largely behind big fluctuations in its performance in recent…

Pfizer Inc.’s COVID-19 vaccine was 73.2% effective against the disease in a trial of children 6 months through 4 years old, reinforcing results that led to the shot’s authorization in young kids in June.

Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated.